pimobendan has been researched along with Cardiac Remodeling, Ventricular in 2 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 7.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 3.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakata, TM | 1 |
| Suzuki, K | 1 |
| Uemura, A | 1 |
| Shimada, K | 1 |
| Tanaka, R | 1 |
| Nonaka, M | 1 |
| Morimoto, S | 1 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 1 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
2 other studies available for pimobendan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Collagen Type I; Collagen Type III; Disease Models, Animal; Fibrosis; | 2019 |
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |